Relmada Therapeutics (RLMD) Change in Acquisitions & Divestments (2020 - 2026)

Relmada Therapeutics (RLMD) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $14.3 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 9.83% year-over-year to $14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.1 million (down 45.31% YoY) and the FY2025 annual result came in at $35.7 million, down 43.92% from the prior year.
• Change in Acquisitions & Divestments advanced to $14.3 million in Q1 2026 per RLMD's latest filing, from $5.9 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $74.8 million in Q1 2023 and bottomed at $5.9 million in Q4 2025.
• The 5-year median for Change in Acquisitions & Divestments is $15.3 million (2024), against an average of $18.9 million.
• The widest annual swing landed in 2022, when Change in Acquisitions & Divestments slumped 86.53%; it then surged 517.79% in 2023.
• Tracing RLMD's Change in Acquisitions & Divestments over 5 years: stood at $6.6 million in 2022, then surged by 517.79% to $41.1 million in 2023, then plunged by 70.77% to $12.0 million in 2024, then sank by 51.2% to $5.9 million in 2025, then soared by 144.04% to $14.3 million in 2026.
• Per Business Quant, the three latest RLMD Change in Acquisitions & Divestments figures stand at $14.3 million (Q1 2026), $5.9 million (Q4 2025), and $7.0 million (Q3 2025).

Peer Comparison